Aviragen Therapeutics (AVIR -3.8%) has postponed its February 13 special shareholders meeting in order to "provide [its] stockholders additional time to consider the revised deal terms" related to its proposed merger with Vaxart.
Under the terms of the original agreement, Aviragen shareholders would own ~40% of the combined company. Under the revised deal, reported two days ago, Aviragen shareholders would own 49% of the combined firm.
Previously: Aviragen to merge with Vaxart (Oct. 30, 2017)
Subscribe for full text news in your inbox